- Home
- FLNC vs KURA Comparison
FLNC vs KURA Comparison
Compare FLNC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- KURA
- Stock Information
- Founded
- FLNC 2018
- KURA 2014
- Country
- FLNC United States
- KURA United States
- Employees
- FLNC N/A
- KURA N/A
- Industry
- FLNC Industrial Machinery/Components
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLNC Miscellaneous
- KURA Health Care
- Exchange
- FLNC Nasdaq
- KURA Nasdaq
- Market Cap
- FLNC 533.2M
- KURA 492.9M
- IPO Year
- FLNC 2021
- KURA N/A
- Fundamental
- Price
- FLNC $5.83
- KURA $5.85
- Analyst Decision
- FLNC Buy
- KURA Strong Buy
- Analyst Count
- FLNC 18
- KURA 12
- Target Price
- FLNC $9.03
- KURA $24.50
- AVG Volume (30 Days)
- FLNC 4.0M
- KURA 1.3M
- Earning Date
- FLNC 08-06-2025
- KURA 08-07-2025
- Dividend Yield
- FLNC N/A
- KURA N/A
- EPS Growth
- FLNC N/A
- KURA N/A
- EPS
- FLNC N/A
- KURA N/A
- Revenue
- FLNC $2,329,871,000.00
- KURA $67,991,000.00
- Revenue This Year
- FLNC $3.61
- KURA $109.86
- Revenue Next Year
- FLNC $25.79
- KURA $107.90
- P/E Ratio
- FLNC N/A
- KURA N/A
- Revenue Growth
- FLNC 6.08
- KURA N/A
- 52 Week Low
- FLNC $3.46
- KURA $5.41
- 52 Week High
- FLNC $24.00
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- FLNC 67.78
- KURA 40.44
- Support Level
- FLNC $4.68
- KURA $5.56
- Resistance Level
- FLNC $5.98
- KURA $7.17
- Average True Range (ATR)
- FLNC 0.37
- KURA 0.38
- MACD
- FLNC 0.10
- KURA -0.06
- Stochastic Oscillator
- FLNC 78.16
- KURA 6.05
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.